Wedmont Private Capital Acquires 247 Shares of Hologic, Inc. (NASDAQ:HOLX)

Wedmont Private Capital boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,357 shares of the medical equipment provider’s stock after purchasing an additional 247 shares during the quarter. Wedmont Private Capital’s holdings in Hologic were worth $338,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. iA Global Asset Management Inc. bought a new stake in shares of Hologic during the first quarter valued at approximately $37,000. Mather Group LLC. purchased a new stake in Hologic in the 1st quarter worth $48,000. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Hologic by 145.3% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 468 shares during the last quarter. Finally, Toth Financial Advisory Corp grew its position in shares of Hologic by 81.1% during the first quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 347 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Hologic

In related news, insider Brandon Schnittker sold 476 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock valued at $1,469,973 in the last ninety days. Company insiders own 1.75% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of a number of research reports. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Royal Bank of Canada raised their target price on shares of Hologic from $81.00 to $82.00 and gave the company a “sector perform” rating in a report on Tuesday, July 30th. Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Evercore ISI increased their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. Finally, Argus boosted their target price on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and an average target price of $87.60.

Hologic Stock Down 0.3 %

Shares of HOLX stock traded down $0.22 during trading hours on Tuesday, reaching $81.55. 1,548,299 shares of the company’s stock were exchanged, compared to its average volume of 1,648,814. The company has a current ratio of 3.99, a quick ratio of 3.29 and a debt-to-equity ratio of 0.51. The company has a market cap of $19.03 billion, a price-to-earnings ratio of 41.55, a P/E/G ratio of 2.64 and a beta of 0.99. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $84.67. The stock’s 50 day moving average is $76.44 and its 200-day moving average is $75.72.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the business posted $0.93 earnings per share. Analysts predict that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.